Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $14 to $16.
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $14 to $16.